IgE plays a critical role in hypersensitivity reactions such as asthma and allergy as well as poorly defined roles in immunity to parasitic helminth infections. The quantity of antigen-specific IgE is thought to affect the intensity of the allergic reaction as well as the perceived level of resistance to parasitic worms. Because most somatic IgE is bound by its receptors, Fc epsilon RI and Fc epsilon RII, and increased expression of IgE receptors also change with cellular activation status, the serum concentration of IgE may not necessarily reflect levels of systemic IgE. Accurate measures of IgE would help to define the bona fide role of this molecule in immunity. Furthermore, improved indicators of systemic antigen-specific IgE could better predict the risk for severe allergic responses. In this report, we demonstrate a simple method for measuring cell-bound IgE in whole blood using basic flow cytometry. This method demonstrates that, in general, cell-bound IgE correlates well with serum levels of IgE. However, discordance in serum and cell-bound IgE levels in some individuals illustrates the inadequacy of using serum levels of IgE as a systemic indicator and validates the need to assay both cell-bound and free IgE
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888851 | PMC |
http://dx.doi.org/10.1016/j.jim.2009.01.012 | DOI Listing |
CEN Case Rep
December 2024
Department of Pediatrics, Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No.748, Zhongshan Middle Road, Songjiang District, Shanghai, 201600, China.
Nephrotic syndrome (NS) and atopic diseases are linked through shared immunological pathways, with allergic triggers often contributing to NS relapses, particularly in immunoglobulin E (IgE)-mediated pathways. Omalizumab, a humanized monoclonal antibody targeting free and cell-bound IgE, is commonly used in treating atopic diseases. We presented a pediatric case with a history of eczema, asthma, and recurrent atopic rhinitis, who first developed NS at age three, responding well to steroid therapy.
View Article and Find Full Text PDFAllergy
August 2024
Department of Immunology, University Clinic for Rheumatology and Immunology, University of Bern, Bern, Switzerland.
Background: Anti-IgE immunotherapy with monoclonal antibodies represents a breakthrough in treatment of severe allergic diseases. However, drawbacks such as short half-life and high price are not negligible. Our objective is to develop an anti-IgE vaccine based on virus-like particles (VLPs) which can induce long-lasting neutralizing IgG anti-IgE antibodies reducing allergic responses without causing intrinsic mast cell activation due to IgE cross-linking.
View Article and Find Full Text PDFJ Invest Dermatol
October 2023
Department of Dermatology, Medical University of Vienna, Vienna, Austria.
Background: The value, if any, of anti-IgE approaches in the treatment of atopic dermatitis has not been fully clarified. Studies using the anti-IgE omalizumab have yielded conflicting results.
Objective: Antibodies with an IgE-suppressive capacity stronger than omalizumab might be more efficacious.
Background: The value of aeroallergen skin testing is not known in IgE deficient individuals (IgE<2.5 kU/L).
Objective: To investigate the utility of skin prick (SPT), intradermal skin testing (IDST) and measuring serum specific IgE (ssIgE) in IgE deficient patients presenting with environmental allergy-like symptoms.
World Allergy Organ J
January 2021
Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria.
Since the discovery of IgE, almost all attention was given to conditions with elevated specific or total IgE levels such as atopy, type I hypersensitivity reactions, or parasitic infestations. Recent prospective and retrospective studies show that having very low IgE levels, such as those seen in IgE deficiency (IgE<2.5 kU/L), is not without clinical consequences.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!